Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8326)	1/17/1999 12:49:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Read Ricks reply to me on VD thread. :-)

To: Bluegreen who wrote (8326)	1/17/1999 12:56:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bluegreen, glad to see you back. Thought you had given up on XOMA eom.

To: Bluegreen who wrote (8326)	1/18/1999 10:08:00 AM
From: Tharos	Read Replies (1) \| Respond to of 17367

*** Blood trials done without consent CHICAGO (AP) - A company conducted an ill-fated blood substitute trial without the informed consent of patients in the study - some of whom died, federal officials say. Baxter International Inc. was able to test the substitute known as HemAssist without consent because of a 1996 change in federal Food and Drug Administration regulations. The changes broke a 50-year standard to get consent for nearly all experiments on humans. They were designed to help research in emergency medicine that could not happen if doctors took the time to get consent. But the problems with the HemAssist trial are prompting some medical ethicists to question the rule change. See infobeat.com